IXS - Innexus Biotechnology Inc (TSXV) - Page 37

So we aren't expecting any news on this at all?

Eventually, yes. Last I heard, the 2nd primate study hadn't been initiated and herein lies the money. Otherwise, I'm looking for a PP at this level especially after RP chimed in on the last PR.

Let's see if they can take out Dundee today...

Here are all the trades for : IXS on 9/ 30/2009.
21 Records Returned

Trades
ExchangeDatePriceChangeVolumeBuyerSellerMarkers
V 2009-09-30 10:05:37 0.095 -0.005 1,860,000 6 Union 27 Dundee K
V 2009-09-30 10:04:20 0.095 -0.005 5,000 1 Anonymous 27 Dundee K
V 2009-09-30 10:03:53 0.095 -0.005 10,000 124 Questrade 27 Dundee K
V 2009-09-30 10:03:36 0.095 -0.005 20,000 1 Anonymous 27 Dundee K
V 2009-09-30 10:03:36 0.095 -0.005 10,000 124 Questrade 27 Dundee K
V 2009-09-30 10:03:27 0.095 -0.005 10,000 124 Questrade 27 Dundee K
V 2009-09-30 10:03:26 0.095 -0.005 5,000 28 BBS 27 Dundee K
V 2009-09-30 10:03:17 0.095 -0.005 10,000 124 Questrade 27 Dundee K
V 2009-09-30 10:02:24 0.095 -0.005 5,000 28 BBS 27 Dundee K
V 2009-09-30 10:01:21 0.095 -0.005 5,000 28 BBS 27 Dundee K
V 2009-09-30 10:00:58 0.095 -0.005 10,000 124 Questrade 27 Dundee K
V 2009-09-30 10:00:39 0.095 -0.005 1,500 1 Anonymous 27 Dundee K
V 2009-09-30 10:00:19 0.095 -0.005 5,000 28 BBS 27 Dundee K
V 2009-09-30 10:00:19 0.095 -0.005 20,000 1 Anonymous 27 Dundee K
V 2009-09-30 10:00:19 0.095 -0.005 23,500 85 Scotia 27 Dundee K
V 2009-09-30 09:51:24 0.105 0.005 5,000 1 Anonymous 1 Anonymous K
V 2009-09-30 09:43:02 0.095 -0.005 1,500 85 Scotia 27 Dundee K
V 2009-09-30 09:32:39 0.10 0.00 25,000 1 Anonymous 27 Dundee K
V 2009-09-30 09:32:39 0.10 0.00 20,000 6 Union 27 Dundee K
V 2009-09-30 09:32:39 0.10 0.00 12,000 9 BMO Nesbitt 27 Dundee K
V 2009-09-30 09:32:39 0.10 0.00 9,500 1 Anonymous 27 Dundee KL

ixs

well its about time

upppp

Volume and price is on the rise

Almost 2 full weeks of down-trend and a gap down today. Starting to look better as a re-entry for those who took advantage of the recent run. IMO.

Stirring once again. 3-week down-trend breach, volume is average and at this rate will likely be 2-3x average by the close (I hate people who make predictions). I'm busy once again FWIW.

Anyone know when the next news release will be out? I have been holding for like for months. Thanks all!

yesterday's new conference seemed positive to me. They are doing all they can to get financing. The deal with RP is not dead as RP is doing their productive review on DXL625. Probably dragging their feet to get money themselves.

They said that they are dealing with 2 large pharmas that they cannot name. They have received antibodies from the pharmas and coverted to DXL and returned them to the pharmas for testing. They said they are far along with one more than the other. They are looking at animal antibodies too.

Golf, who do you post as on SH?

InNexus Biotechnology Develops New Psoriasis Product Based on Its Skin Permeating Antibody Technology
Last Update: 1/5/2010 4:24:00 PM



SCOTTSDALE, Ariz., Jan 05, 2010 (BUSINESS WIRE) -- InNexus Biotechnology Inc. (TSX.V: IXS) ( www.ixsbio.com ), a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL(TM)) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab(TM) technology.

Scientists at InNexus have designed and produced by recombinant technology, a novel antibody product directed at treatment of psoriasis, an autoimmune skin disease. The product, designated IXSCD11a, is being formulated for topical use either as a lotion or in patches to be applied to affected areas. IXSCD11a is an antibody fragment based on InNexus' Transmab technology that penetrates cell membranes and dermal barriers. IXSCD11a has shown significant increase in cell penetration compared to other products targeting psoriasis.

Dr. Thomas Kindt, InNexus' CSO, said, "The target bound by the antibody fragment is a cell surface molecule involved in inflammation, which is a factor in the development of psoriasis, as well as a number of other autoimmune conditions. It binds the CD11a receptor that is key to the immune cell-cell interactions that lead to inflammatory processes causative of the painful and disfiguring psoriatic lesions. A full-length antibody product previously marketed by another company with specificity for this receptor was used successfully for treatment of the most serious forms of psoriasis, but was withdrawn due to incidences of fatal brain infection caused by systemic immunosuppression. IXSCD11a was designed to circumvent this side effect because low molecular weight antibody fragments do not persist in circulation long enough to mediate systemic immune suppression. In contrast to full-length antibodies that persist in the bloodstream with half-lives of 18-24 days, antibody fragments like IXSCD11a are eliminated within three hours. Immune-suppressive activity of IXSCD11a is likely to be confined to the region of application and eliminated rapidly."

Jeff Morhet, CEO of InNexus, said, "2009 might have been a year for survival, but 2010 is a year for biotech companies to differentiate and show their value. It is our aim to develop safe and effective treatments for disease conditions that cause physical and mental suffering to millions of people. Our IXSCD11a product combines the proven efficacy of previous products with a desired and reassuring safety profile. This is exciting science."

According to the National Psoriasis Foundation ( http://www.psoriasis.org ), psoriasis affects 125 million people worldwide (2-3% of total population) and is present in all racial groups in varying rates. Psoriasis is the most prevalent autoimmune disease in the U.S., affecting 7.5 million people.

InNexus Resources

Market likes the news. Was up 81% a few minutes ago.

Lots of talk of this getting up to .40 or more!!!!!!!
Exciting to find out how things go the next little while. IT should be a great year for IXS

Why stop at the $0.40 predictions when SH is loaded with dollar figures. Lol. Results usually help before predictions.

good volume and SP gain thus far...anyone know whats up?

No, but something definitely seems to be going on. It's definitely maybe. lol

LMAO.

I hope it's not another penny up before two pennies or more down... not holding my breathe though. If it wasn't in my TFSA, I'd secure my loss and deny I even knew what IXS stood for. But GLTA

InNexus Biotechnology Announces Increase in Loan Facility of USD$1.0 Million
BRITISH COLUMBIA, CANADA – 19 February 2010 - InNexus Biotechnology Inc., (TSX VENTURE: IXS.V,
http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies
based on its Dynamic Cross Linking (DXL) technology, is pleased to announce that the Company has increased its loan
facility with a group of investors by $1.0 million for an aggregate amount of up to USD$3.5 million.
The loan facility bears interest at 12.5% payable in cash or in Common Shares of InNexus, subject to regulatory approval,
and matures 6 months from the date of drawdown. InNexus is entitled to extend the term for a further 6 months. The
loans are repayable at any time subject to a 5% penalty. In connection with the loan, InNexus will issue to the lenders at
closing common share purchase warrants obtained by a) dividing each lender’s loan value by b) the then prevailing
market price c) multiplied by 25%. Each warrant will entitle the holder to acquire one common share of InNexus at a price
equal to the then prevailing market price, which shall be the same as b), above. The purchase warrants are exercisable
for the earlier of a period of 60 months from closing or complete repayment of the loan.
Proceeds of the loan facility are intended to be used for paying current liabilities and operating expenses for InNexus’
continued research and development programs.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL
technology, which improves the potency of existing antibody products while opening new markets and disease
applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of
Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein
and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and
diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this
news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve
inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may
cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact

David Petulla
Chief Financial Officer
InNexus Biotechnology Inc.
480-862-7500

This recent news on financing is what was alluded to in the recent CC. Now that it's out of the way, volume is picking up and the bottom is all but confirmed. Keep an eye on Weisel--once they've dried up, it'll likely be time to move.

Here are all the trades for : IXS on 2/22/2010.
27 Records Returned

Trades
Exchange Date Price Change Volume Buyer Seller Markers
V 2010-02-22 15:46:34 0.06 0.00 50,000 79 CIBC 82 Thomas Weisel K
V 2010-02-22 15:46:27 0.06 0.00 6,000 85 Scotia 82 Thomas Weisel K
V 2010-02-22 15:46:27 0.06 0.00 54,000 85 Scotia 7 TD Sec K
V 2010-02-22 15:46:04 0.06 0.00 46,000 1 Anonymous 7 TD Sec K
V 2010-02-22 15:46:04 0.06 0.00 4,000 1 Anonymous 82 Thomas Weisel K
V 2010-02-22 15:45:53 0.06 0.00 50,000 1 Anonymous 82 Thomas Weisel K
V 2010-02-22 14:28:15 0.06 0.00 15,000 9 BMO Nesbitt 82 Thomas Weisel K
V 2010-02-22 13:57:49 0.06 0.00 30,000 2 RBC 82 Thomas Weisel K
V 2010-02-22 13:51:21 0.06 0.00 1,000 2 RBC 82 Thomas Weisel K
V 2010-02-22 13:33:58 0.06 0.00 500 79 CIBC 95 Wolverton E
V 2010-02-22 12:41:54 0.06 0.00 1,000 79 CIBC 82 Thomas Weisel K
V 2010-02-22 12:41:54 0.06 0.00 100,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:48 0.06 0.00 29,000 2 RBC 82 Thomas Weisel K
V 2010-02-22 10:04:41 0.06 0.00 70,000 2 RBC 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 30,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 20,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 20,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 156,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 50,000 9 BMO Nesbitt 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 20,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 5,000 7 TD Sec 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 18,000 2 RBC 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 1,000 19 Desjardins 82 Thomas Weisel K
V 2010-02-22 10:04:20 0.06 0.00 1,000 19 Desjardins 82 Thomas Weisel K
V 2010-02-22 09:45:22 0.065 0.005 148,000 85 Scotia 82 Thomas Weisel K
V 2010-02-22 09:37:57 0.065 0.005 500 95 Wolverton 85 Scotia E
V 2010-02-22 09:37:57 0.065 0.005 6,000 85 Scotia 85 Scotia KL

Looking very good!